In May, we were honoured to deliver presentations at the 88th Annual Scientific Congress of the Royal Australasian College of Surgeons, held in Bangkok. Over 1750 delegates attended the Congress from Australia, New Zealand, and around the world. Many of our colleagues inspired us with the discoveries they shared.
We’re honoured to receive further recognition of our work in Dupuytren’s Disease — a debilitating condition affecting the hands. Dr Kirin Tan co-authored the winning paper with our team when he was a medical student at Auckland University doing an elective at the GMRI. The paper, titled The Role of Stem Cells in Dupuytren’s Disease: A Review, won the Best Oceanic Paper Award from Plastic and Reconstructive Surgery Global Open, a prestigious international journal.
For a former research technician, Matt Munro says the GMRI has been the perfect place to undertake his PhD. Matt is investigating the role of cancer stem cells (CSCs) and the renin-angiotensin system in colon cancer.
Erin Paterson coordinates the vital cell culture and tissue banking programme for the GMRI’s primary cell lines. After taking tissues donated by patients to the GMRI and growing cells from them, these cells are used for the GMRI’s research.
We love working with our interns and fostering the next generation of scientists and medical experts. They contribute to our wide range of research on cancers and other conditions. This year we have had three interns outside of our usual summer studentship programme, with Tessa Pilkington, Claire Luke-Krishnan, and Jazmean Williams joining us for four months. We’ve asked them questions about their internship experience.
Since the GMRI opened its state-of-the art laboratory facility in Newtown, Wellington, we’ve gained approval for four clinical trials to test our novel cancer treatment based on our discoveries in the lab. We didn’t expect to be here in just five years — we thought it would take much longer. At the recent Royal Australasian College of Surgeons’ Annual Scientific Congress in Bangkok we heard many comments from colleagues who are excited about our work. They see our approach to cancer treatment as unique and radical.